 Connection
Sarah Parker to Mycobacterium tuberculosis
This is a "connection" page, showing publications Sarah Parker has written about Mycobacterium tuberculosis.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.442 |
|
|
|
-
Parker SK, Barkley RM, Rino JG, Vasil ML. Mycobacterium tuberculosis Rv3802c encodes a phospholipase/thioesterase and is inhibited by the antimycobacterial agent tetrahydrolipstatin. PLoS One. 2009; 4(1):e4281.
Score: 0.225
-
Kim S, Yamada WM, Duncanson B, Nole J, Rogers S, Parker S, Bacci M, Mtchedlidze N, Peloquin CA, Louie A, Schmidt S, Drusano GL, Neely MN. Building Optimal Three-Drug Combination Chemotherapy Regimens To Eradicate Mycobacterium tuberculosis in Its Slow-Growth Acid Phase. Antimicrob Agents Chemother. 2021 09 17; 65(10):e0069321.
Score: 0.134
-
Parker SK, Curtin KM, Vasil ML. Purification and characterization of mycobacterial phospholipase A: an activity associated with mycobacterial cutinase. J Bacteriol. 2007 Jun; 189(11):4153-60.
Score: 0.050
-
Labuda SM, McDaniel CJ, Talwar A, Braumuller A, Parker S, McGaha S, Blissett C, Wortham JM, Mukasa L, Stewart RJ. Tuberculosis Outbreak Associated With Delayed Diagnosis and Long Infectious Periods in Rural Arkansas, 2010-2018. Public Health Rep. 2022 Jan-Feb; 137(1):94-101.
Score: 0.033
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|